Table of Contents
International Scholarly Research Notices
Volume 2014 (2014), Article ID 631501, 6 pages
http://dx.doi.org/10.1155/2014/631501
Clinical Study

Efficacy of Levofloxacin Based Triple and High-Dose PPI-Amoxicillin Dual Eradication Therapy for Helicobacter pylori after Failures of First- and Second-Line Therapies

1Department of Gastroenterology and Nephrology, Graduate School of Medicine, Chiba University, Inohana 1-8-1, Chiba City 260-8670, Japan
2Department of Clinical Laboratory, Chiba University Hospital, Japan

Received 10 September 2014; Revised 14 November 2014; Accepted 1 December 2014; Published 17 December 2014

Academic Editor: Vikram Kate

Copyright © 2014 Kenichiro Okimoto et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. Miwa, N. Sasaki, K. Sugano et al., “Recurrent peptic ulcers in patients with following successful Helicobacter pylori eradication: a multicenter study of 4940 patients,” Helicobacter, vol. 9, no. 1, pp. 9–16, 2004. View at Publisher · View at Google Scholar
  2. N. Uemura, S. Okamoto, S. Yamamoto et al., “Helicobacter pylori infection and the development of gastric cancer,” The New England Journal of Medicine, vol. 345, no. 11, pp. 784–789, 2001. View at Publisher · View at Google Scholar · View at Scopus
  3. T. Takahashi, T. Yujiri, K. Shinohara et al., “Molecular mimicry by Helicobacter pylori CagA protein may be involved in the pathogenesis of H. pylori-associated chronic idiopathic thrombocytopenic purpura,” British Journal of Haematology, vol. 124, no. 1, pp. 91–96, 2004. View at Publisher · View at Google Scholar · View at Scopus
  4. P. Malfertheiner, F. Megraud, C. O'Morain et al., “Current concepts in the management of Helicobacter pylori infection: the Maastricht III consensus report,” Gut, vol. 56, no. 6, pp. 772–781, 2007. View at Publisher · View at Google Scholar · View at Scopus
  5. K. Fukase, M. Kato, S. Kikuchi et al., “Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: an open-label, randomised controlled trial,” The Lancet, vol. 372, no. 9636, pp. 392–397, 2008. View at Publisher · View at Google Scholar · View at Scopus
  6. M. Asaka, M. Kato, and D. Y. Graham, “Strategy for eliminating gastric cancer in Japan,” Helicobacter, vol. 15, no. 6, pp. 486–490, 2010. View at Publisher · View at Google Scholar · View at Scopus
  7. M. Sasaki, N. Ogasawara, K. Utsumi et al., “Changes in 12-year first-line eradication rate of Helicobacter pylori based on triple therapy with proton pump inhibitor, amoxicillin and clarithromycin,” Journal of Clinical Biochemistry and Nutrition, vol. 47, no. 1, pp. 53–58, 2010. View at Publisher · View at Google Scholar · View at Scopus
  8. T. Matsuhisa, T. Kawai, T. Masaoka et al., “Efficacy of Metronidazole as second-line drug for the treatment of Helicobacter pylori infection in the Japanese population: a multicenter study in the Tokyo metropolitan area,” Helicobacter, vol. 11, no. 3, pp. 152–158, 2006. View at Publisher · View at Google Scholar
  9. D. Asaoka, A. Nagahara, and T. Matsuhisa, “Trends of second-line eradication therapy for Helicobacter pylori in Japan: a multicenter study in the Tokyo metropolitan area,” Helicobacter, vol. 18, no. 6, pp. 468–472, 2013. View at Publisher · View at Google Scholar · View at Scopus
  10. T. Rokkas, P. Sechopoulos, I. Robotis, G. Margantinis, and D. Pistiolas, “Cumulative H. pylori eradication rates in clinical practice by adopting first and second-line regimens proposed by the maastricht III consensus and a third-line empirical regimen,” The American Journal of Gastroenterology, vol. 104, no. 1, pp. 21–25, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. K. Murakami, T. Furuta, T. Ando et al., “Multi-center randomized controlled study to establish the standard third-line regimen for Helicobacter pylori eradication in Japan,” Journal of Gastroenterology, vol. 48, no. 10, pp. 1128–1135, 2013. View at Publisher · View at Google Scholar · View at Scopus
  12. Y. Hirata, T. Ohmae, A. Yanai et al., “Sitafloxacin resistance in Helicobacter pylori isolates and sitafloxacin-based triple therapy as a third-line regimen in Japan,” International Journal of Antimicrobial Agents, vol. 39, no. 4, pp. 352–355, 2012. View at Publisher · View at Google Scholar · View at Scopus
  13. J. Matsuzaki, H. Suzuki, T. Nishizawa et al., “Efficacy of sitafloxacin-based rescue therapy for Helicobacter pylori after failures of first- and second-line therapies,” Antimicrobial Agents and Chemotherapy, vol. 56, no. 3, pp. 1643–1645, 2012. View at Publisher · View at Google Scholar · View at Scopus
  14. J. Tankovic, C. Lascols, Q. Sculo, J.-C. Petit, and C.-J. Soussy, “Single and double mutations in gyrA but not in gyrB are associated with low- and high-level fluoroquinolone resistance in Helicobacter pylori,” Antimicrobial Agents and Chemotherapy, vol. 47, no. 12, pp. 3942–3944, 2003. View at Publisher · View at Google Scholar · View at Scopus
  15. K. Murakami, T. Okimoto, M. Kodama et al., “Sitafloxacin activity against Helicobacter pylori isolates, including those with gyrA mutations,” Antimicrobial Agents and Chemotherapy, vol. 53, no. 7, pp. 3097–3099, 2009. View at Publisher · View at Google Scholar · View at Scopus
  16. M. Song and T. L. Ang, “Second and third line treatment options for Helicobacter pylori eradication,” World Journal of Gastroenterology, vol. 20, no. 6, pp. 1517–1528, 2014. View at Publisher · View at Google Scholar · View at Scopus
  17. T. Furuta, N. Shirai, F. Xiao et al., “High-dose rabeprazole/amoxicillin therapy as the second-line regimen after failure to eradicate H. pylori by triple therapy with the usual doses of a proton pump inhibitor, clarithromycin and amoxicillin,” Hepato-Gastroenterology, vol. 50, no. 54, pp. 2274–2278, 2003. View at Google Scholar · View at Scopus
  18. N. Shirai, M. Sugimoto, C. Kodaira et al., “Dual therapy with high doses of rabeprazole and amoxicillin versus triple therapy with rabeprazole, amoxicillin, and metronidazole as a rescue regimen for Helicobacter pylori infection after the standard triple therapy,” European Journal of Clinical Pharmacology, vol. 63, no. 8, pp. 743–749, 2007. View at Google Scholar · View at Scopus
  19. K.-L. Goh, J. Manikam, and C.-S. Qua, “High-dose rabeprazole-amoxicillin dual therapy and rabeprazole triple therapy with amoxicillin and levofloxacin for 2 weeks as first and second line rescue therapies for Helicobacter pylori treatment failures,” Alimentary Pharmacology & Therapeutics, vol. 35, no. 9, pp. 1097–1102, 2012. View at Publisher · View at Google Scholar · View at Scopus
  20. T. Furuta, N. Shirai, M. Kodaira et al., “Pharmacogenomics-based tailored versus standard therapeutic regimen for eradication of H. pylori,” Clinical Pharmacology & Therapeutics, vol. 81, no. 4, pp. 521–528, 2007. View at Publisher · View at Google Scholar · View at Scopus
  21. J. Y. Lee, N. Kim, M. S. Kim et al., “Factors affecting first-line triple therapy of Helicobacter pylori including CYP2C19 genotype and antibiotic resistance,” Digestive Diseases and Sciences, vol. 59, pp. 1235–1243, 2014. View at Publisher · View at Google Scholar · View at Scopus
  22. T. Furuta, N. Shirai, M. Takashima et al., “Effects of genotypic differences in CYP2C19 status on cure rates for Helicobacter pylori infection by dual therapy with rabeprazole plus amoxicillin,” Pharmacogenetics, vol. 11, no. 4, pp. 341–348, 2001. View at Google Scholar · View at Scopus